Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
News & media
Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
Convergent Therapeutics Announces Presentations at the 2023 ASCO Genitourinary (GU) Cancers Symposium on its Lead Candidate
Convergent Therapeutics Banking on Radioantibody Approach for PSMA-Targeted mCRPC Treatment
Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer
Convergent Therapeutics Appoints Alexander Brown as Chief Operating Officer
Convergent Therapeutics Appoints Philip Kantoff, M.D. as Chief Executive Officer